semaglutide (Ozempic)

Clinical studies are cited showing that up to 40% of total weight lost on GLP-1 receptor agonists can be lean muscle mass rather than fat. The speaker frames this as a well-established but under-discussed finding from the clinical trial literature. No specific study or sample size is named.

The speaker's clinic protocol to mitigate GLP-1-associated muscle loss includes: protein-first eating at every meal (minimum 100g/day, ideally 150g+), resistance training 3x/week, and strategic calorie targets to avoid excessive deficit. The speaker claims dramatically different lean mass outcomes in patients following this protocol versus unguided patients. No controlled data from the clinic is presented.

The speaker claims that muscle loss from GLP-1 therapy reduces resting metabolic rate, which is the primary mechanism behind weight regain after discontinuation. This is presented as a clinical observation explaining rebound weight gain post-cessation, not tied to a specific study.